According to MRFR, the Global Cerebrospinal Fluid Management Devices Market is poised to register a CAGR of 5.34% over the review period and reach USD 2.10 Billion by 2027. In recent years, the market for cerebrospinal fluid control equipment has grown and there are a lot attributable to the growing number of cases of hydrocephalus.
It has been noted that hospitals and several other health care organisations are committed to the treatment of patients suffering from this lethal disease since the onset of the current coronavirus pandemic. This has resulted in a loss of necessary prescription equipment and attempts are being made exclusively by healthcare practitioners to use medical supplies. The reduction is primarily due to worldwide inventory supply and demand mismatches due to the outbreak of COVID-19. Owing to the prohibitions enforced by governments in different countries to close down factories or work with limited staffing in order to contain the transmission of the virus and keep the workers healthy, there is insufficient production of devices used in the treatment of neurological diseases. However, considering the challenging situation in which the highest health services are diverted to the care of covid-19 infected people, including hospital beds and other treatment rooms, attempts are being made to pay attention to life-threatening emergencies such as hydrocephalus, so demand development is expected to rise at a steady rate in the current coronavirus pandemic scenario.
Growing Prevalence of Chronic Diseases to Drive Market Growth
Increasing prevalence of neurological diseases, increasing geriatric population, high demand for minimally invasive surgery, increasing disposable incomes, improvement of health facilities, and advancement of advanced technologies are the main factors that lead to the growth of the market for cerebrospinal fluid (CSF) management products. Market development is expected to be boosted by growing cases of hydrocephalus prevalence & subsequent ventriculomegaly. Implementing new and improved sensor is the latest trend in the cerebrospinal fluid devices market, this may provide the market with the much-needed boost to improve its growth rate while at the same time improving quality of the diagnosis.
Growing R&D Investments to Create New Opportunities for Key Players
Factors such as corporate acquisition, product growth, and continuous market research & development (R&D) have opened up new possibilities for producers of cerebrospinal fluid control instruments. The launch of new products and technical developments has contributed to the treatment of multiple neurovascular conditions by hospitals, which would create attractive prospects for business growth over the prognosis period.
Surgical Complications to Impede Market Growth
Hydrocephalus should be treated using a shunt device and complications are frequently included with this procedure. Malfunction, inflammation, and shunt obstruction are among the most serious shunt complications. Strict regulatory guidelines can take longer for the product to be launched and raise the total cost of product production, thereby influencing the demand.
Global Cerebrospinal Fluid Management Devices Market is segmented based on the Age Group, Product, and End User.
The market, based on product, has been categorized into critical care products, shunts & valves, dural sealants, and others. Among these, shunts & valve is the most signficant segment. Additionally, an extensive number of companies are increasingly focusing towards product development.
The global market for cerebrospinal fluid management devices has been divided into paediatric, adult, and geriatric, depending on age level. Of both, the high prevalence of hydrocephalus in the paediatric community makes paediatrics the largest category. Hydrocephalus is born about every one or two out of every 1,000 babies across the globe.
The global demand for end-user-based cerebrospinal fluid control systems has been split into hospitals, outpatient settings, and research and academic institutions. Hospitals & clinics accounted for the highest market share of these. The development of the hospitals & clinics sector will be accelerated by the growing introduction of cerebrospinal fluid control equipment and an increase in the number of hospitals. The growing number of hospitals would then need a growing number of neurosurgery procedures and a highly trained workforce to fuel market growth.
The geographical overview of the global market has been conducted in four major regions, including the Asia Pacific, North America, Europe, and the rest of the world.
Superior Healthcare Infrastructure to Drive Americas growth
Owing to the presence of medical equipment suppliers and a well-established healthcare sector, along with expanded adoption of medical practitioners, the Americas dominated the market and accounted for the largest share in 2019. In North America, due to the involvement of major industry participants, existing healthcare facilities, high visibility, and accessibility to innovative treatment alternatives, the US had the largest market share in 2019. This is therefore propelling the market for instruments for cerebrospinal fluid treatment, thereby fostering the region's supremacy.
Expansion of Key players Regional Footprint to Drive Market Growth
Owing to the increase in the biopharmaceutical industry, the involvement of major suppliers, government funding for research and development and the growing geriatric population, Europe accounts for the second largest share of the global demand for cerebrospinal fluid control products. Degenerative diseases and chronic conditions that may lead to neurological diseases at a later stage are more important in the geriatric community.
APAC to Account as the Fastest-growing Region
Due to rising per capita health expenditure, increasing understanding of hydrocephalus, and increasing study funding, Asia-Pacific is expected to be the fastest-growing market during the projected period. This has contributed to the expansion of the Asia-Pacific market for cerebrospinal fluid control instruments.
MEA to Witness Gradual Growth
The demand for cerebrospinal fluid control products in the Middle East & Africa is segmented into two primary areas, namely the Middle East and Africa. Due to increasing medical tourism, increased R&D investment, the growth of healthcare facilities, the expansion of international corporations, and increased favourability and regulatory regulations in the region, the Middle East will have a considerable market share in this region over the measurement period. Thus, these variables are projected to have a positive effect on the demand in the Middle East and Africa over the review period.
June 2020: Rhaeos, Inc. (Rhaeos), a private medical technology company focused on solving the unmet therapeutic need for hydrocephalus patients due to excess cerebrospinal fluid, announced its initial application, FlowSense, a wearable, non-invasive flow monitor, has been awarded the FDA Breakthrough System Designation.
June 2020: A minimally invasive implant for the treatment of hydrocephalus caused by excess cerebrospinal fluid was developed by CereVasc, who raised USD 43.9 million to help begin first-in-human clinical trials. The overall aim of the business was to turn the operation into an outpatient, one-day solution to surgery. The goal of the eShunt was also to fix the catheter obstructions, infections and problems of over-drainage seen in other schemes.
By Age Group
|Market Size||USD 2.10 Billion|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors and Trends|
|Segments Covered||Age Group, Product and End User|
|Geographies Covered||Revenue Forecast, Competitive Landscape, Growth Factors and Trends|
|Key Vendors||Medtronic Plc (Ireland), Natus Medical Incorporated (US), Braun Melsungen AG (Germany), Sophia (France), IRRAS AB (Sweden), Möller Medical GmbH (Germany), Argi Grup (Turkey), Longeviti (US), Integra Lifesciences Corporation (US)|
|Key Market Opportunities||
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
The outlook of the global cerebrospinal fluid management devices market looks very promising.
The global cerebrospinal fluid management devices market is projected to grow at approximately 4.5% CAGR during forecast period (2018-2023).
Increasing awareness about hydrocephalus.
North America holds the largest share in the global cerebrospinal fluid management devices market followed by Europe and Asia Pacific, respectively.
Integra LifeSciences Holdings Corporation, Medtronic plc, B. Braun Melsungen AG, Spiegelberg GmbH & Co. KG, DePuy Synthes, SOPHYSA, Dispomedica GmbH, Natus Medical Incorporated, Delta Surgical Limited, Moller Medical GmbH, Argi Grup, G. SURGIWEAR LTD., BeckerSmith Medical, Inc., and Wellong Instruments Co., Ltd., are some of the major players operating in the cerebrospinal fluid management devices market.